Heidelberg (pta037/29.01.2021/17:45) - 4basebio AG (in future 2invest AG; Frankfurt: 2INV; ISIN: DE000A2YN801; Prime Standard) announces that the transfer of the registered office of 4basebio SE has become effective by registration at Companies House of England and Wales on 22 December 2020 and that this company is meanwhile registered as 4basebio UK Societas (4basebio UK) under number SE000143 at Companies House.
As consideration for the transfer of the assets spun off to 4basebio UK, the shareholders of 4basebio AG will receive one share in 4basebio UK for every six 4basebio AG shares they have held to date. In total, 8,622,231 shares in 4basebio UK (GB00BLD8ZL39) will be granted to the shareholders of 4basebio AG.
Since all shares of 4basebio AG are held in collective safe custody accounts, the shareholders do not need to take any action regarding the allotment of shares.
The technical separation of the 4basebio UK shares from the 4basebio AG shares will take place on 3 February 2021 ("Ex Day"). Trading and listing of the shares on the regulated market of the Frankfurt Stock Exchange (Prime Standard) as well as on the Open Market of all other German stock exchanges will thus take place "ex spin-off" as of 3 February 2021. The allotment of 4basebio UK Shares to eligible 4basebio AG shareholders by way of depositary credit is expected to take place on 11 February 2021. A corresponding allotment announcement will be published in the German Federal Gazette (Bundesanzeiger).
It is expected that the 4basebio UK registered shares, which will be admitted to the CREST Clearing System through Euroclear, will commence trading on 17 February 2021 following admission to the Alternative Investment Market (AIM) segment of the London Stock Exchange.
About 4basebio AG:
4basebio AG (to be renamed to 2invest AG by resolution of the Extraordinary General Meeting on 28 January 2021) is a listed company which acquires, holds, manages and sells investments in corporations and partnerships, in particular - but not exclusively - in the biotechnology, life science and IT sectors in Germany and abroad.
Global investments or investments in unlisted companies or financial instruments are also possible. Investment decisions are made based on attractive risk-reward profiles. The focus is on achieving a risk-adequate, long-term total return. The company is listed in the Prime Standard of the Frankfurt Stock Exchange (Ticker: 2INV; ISIN: DE000A2YN801).
More information: https://www.4basebioag.com
For further information please contact:
Board of Directors
Dr Robert Mayer, Manager IR
Tel: +49 171 3876540
# # # This publication is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Certain statements contained in this press release that do not relate to proven financial results or other historical data should be considered forward-looking, meaning that such statements are primarily predictions of future results, trends, plans or objectives. These statements should not be considered as total guarantees because, by their nature, they are subject to known and unknown risks and uncertainties and may be affected by other factors that could cause 4basebio AG's actual results, plans and objectives to differ materially from any stated conclusions or implied predictions contained in such statements. 4basebio undertakes no obligation to publicly update or revise any of these statements, whether as a result of new information, future results or otherwise. # #(end)
Waldhofer Str. 102
|contact person:||Robert Mayer|
|phone:||+49 171 3876540|
|stock exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|